09899322

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1626kas

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
NEWS   3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS   4  Apr 09  ZDB will be removed from STN
NEWS   5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS   6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS   7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
NEWS   8  Apr 22  Federal Research in Progress (FEDRIP) now available
NEWS   9  Jun 03  New e-mail delivery for search results now available
NEWS  10  Jun 10  MEDLINE Reload
NEWS  11  Jun 10  PCTFULL has been reloaded
NEWS  12  Jul 02  FOREGE no longer contains STANDARDS file segment
NEWS  13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
NEWS  14  Jul 29  Enhanced polymer searching in REGISTRY
NEWS  15  Jul 30  NETFIRST to be removed from STN
NEWS  16  Aug 08  CANCERLIT reload
NEWS  17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
NEWS  18  Aug 08  NTIS has been reloaded and enhanced
NEWS  19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
NEWS  20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS  21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
NEWS  22  Aug 26  Sequence searching in REGISTRY enhanced
NEWS  23  Sep 03  JAPIO has been reloaded and enhanced
NEWS  24  Sep 16  Experimental properties added to the REGISTRY file
NEWS  25  Sep 16  CA Section Thesaurus available in CAPLUS and CA
NEWS  26  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
NEWS  27  Oct 21  EVENTLINE has been reloaded
NEWS  28  Oct 24  BEILSTEIN adds new search fields
NEWS  29  Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
NEWS  30  Oct 25  MEDLINE SDI run of October 8, 2002
NEWS  31  Nov 18  DKILIT has been renamed APOLLIT
NEWS  32  Nov 25  More calculated properties added to REGISTRY
NEWS  33  Dec 02  TIBKAT will be removed from STN
NEWS  34  Dec 04  CSA files on STN
NEWS  35  Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS  36  Dec 17  TOXCENTER enhanced with additional content
NEWS  37  Dec 17  Adis Clinical Trials Insight now available on STN
NEWS  38  Dec 30  ISMEC no longer available
NEWS  39  Jan 13  Indexing added to some pre-1967 records in CA/CAPLUS

NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
              CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
```

Kamal Saeed

09899322

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:04:14 ON 16 JAN 2003

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:04:23 ON 16 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JAN 2003 HIGHEST RN 479190-61-9
DICTIONARY FILE UPDATES: 15 JAN 2003 HIGHEST RN 479190-61-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\098993222.str

L1 STRUCTURE UPLOADED

Kamal Saeed

09899322

=> que L1

L2 QUE L1

=> D
L2 HAS NO ANSWERS
L1 STR



G1 Cl,Br,F,I,CN

Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

=> S L1 FULL
FULL SEARCH INITIATED 13:05:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 14697 TO ITERATE

100.0% PROCESSED 14697 ITERATIONS 1530 ANSWERS
SEARCH TIME: 00.00.01

L3 1530 SEA SSS FUL L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\098993222.str

L4 STRUCTURE UPLOADED

=> que L4

Kamal Saeed

09899322

L5 QUE L4

=> D
L5 HAS NO ANSWERS
L4 STR



G1 Cl,Br,F,I,CN

G2 CH2,CH,SO2,C,S

Structure attributes must be viewed using STN Express query preparation.
L5 QUE ABB=ON PLU=ON L4

=> S L4 FULL
FULL SEARCH INITIATED 13:14:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 16724 TO ITERATE

100.0% PROCESSED 16724 ITERATIONS 1541 ANSWERS
SEARCH TIME: 00.00.01

L6 1541 SEA SSS FUL L4

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	302.30	302.51

FILE 'CAPLUS' ENTERED AT 13:14:33 ON 16 JAN 2003

Kamal Saeed

09899322

FILE COVERS 1907 - 16 Jan 2003 VOL 138 ISS 3
FILE LAST UPDATED: 15 Jan 2003 (20030115/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> S L6
L7          559 L6

=> S L7/THU
FIELD CODES CANNOT BE CHANGED HERE
You may have tried to apply a field code to a term that already has a
field code.  You can only add a field code to a term that has no field
code appended to it.

=> S L6/THU
            559 L6
         485382 THU/RL
L8           14 L6/THU
                    (L6 (L) THU/RL)

=> D IBIB ABS HITSTR TOT
```

Kamal Saeed

09899322

L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:964349 CAPLUS
TITLE: Preparation of pyrazoles as HIV reverse transcriptase inhibitors
INVENTOR(S): Dymock, Brian William; Gill, Adrian Liam; Jones, Philip Stephen; Parkes, Kevin Edward Burdon; Parratt, Martin John
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100853	A1	20021219	WO 2002-EP5898	20020529

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-13524 A 20010604
GI



I

AB The title compds. [I; R1 = (un)substituted alkyl; R2 = (un)substituted aryl; R3 = OH, NH2, N3, OH, etc.; A = (un)substituted alkyl, arylmethyl, heterocyclylmethyl, etc.] which are inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication, and consequently may be used as therapeutic agents for HIV mediated process, were prepd. E.g., a 9-step synthesis of I [R1 = iso-Pr; R2 = 3,5-Cl2C6H3; R3 = OH; A = (4-pyridyl)methyl], starting with tert-Bu carbazate and acetone, was given. The compds. I range in IC50 activity from about 0.5 to about 5000 nM in the anti-HIV assay.
IT **478620-45-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazoles as HIV reverse transcriptase inhibitors)
RN 478620-45-0 CAPLUS

L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:51437 CAPLUS
DOCUMENT NUMBER: 136:118445
TITLE: Pyrazole derivatives useful as reverse transcriptase inhibitors, for the treatment of HIV infection, and their use, formulations, and preparation
INVENTOR(S): Corbau, Romuald Gaston; Mowbray, Charles Eric; Perros, Manoussos; Stupple, Paul Anthony; Wood, Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004424	A1	20020117	WO 2001-IB1174	20010621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001067766	A5	20020121	AU 2001-67766	20010621
US 2002032184	A1	20020314	US 2001-899322	20010705

PRIORITY APPLN. INFO.: GB 2000-16787 A 20000707
US 2000-220087P P 20000721
WO 2001-IB1174 W 20010621
OTHER SOURCE(S): MARPAT 136:118445
GI



I II

AB The invention relates to the use of pyrazole derivs. I and pharmaceutically acceptable salts and solvates thereof, in the manuf. of a reverse transcriptase inhibitor or modulator, to certain novel pyrazole derivs. among these, and to processes for the prepn. of and compns. contg. such novel derivs. [wherein: (i) R1 = H, (un)substituted (cyclo)alkyl, Ph, or benzyl, halo, cyano, OH derivs., CO2H or derivs., NH2 or derivs., etc.; R2 = H or -YZ; or (ii) R1R2 = C3-4 alkylene where one CH2 may be replaced by O or (un)substituted NH; Y = bond or C1-3 alkylene; Z = (un)substituted alk(en/yn)yl, cycloalkyl, Ph, benzyl, or certain acylated or sulfonylated amino groups; R3 = H, (un)substituted (cyclo)alkyl, Ph, benzyl, cyano, halo, OH derivs., CO2H or derivs., NH2 or derivs.; R4 = (un)substituted Ph or pyridyl; X = (un)substituted CH2, CO, S, SO, or SO2]. The compds. are useful for treating infection by HIV or genetically related retroviruses, or a resultant case of AIDS. Examples include over 90 invention compds. and over 50 prepd. intermediates. For instance, coupling of 3-chloro-2,4-pentanedione with 3,5-dichlorothiophenol in the presence of NaI and K2CO3 gave the intermediate 3-[(3,5-dichlorophenyl)sulfanyl]-2,4-pentanedione. Cyclocondensation of this dione with (2-hydroxyethyl)hydrazine gave the invention pyrazole II. All example compds. inhibited recombinant HIV-1 reverse transcriptase in vitro with IC50 values of < 100 .mu.M.
IT **390355-01-8P**, 2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **390355-06-3P**, Ethyl [4-(3,5-dichlorobenzyl)-3-isopropyl-5-methyl-1H-pyrazol-1-yl]acetate **390355-10-9P**, 4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazole **390355-16-5P**, 4-(3,5-Dichlorobenzyl)-3-isopropyl-5-methyl-1H-pyrazole **390355-17-6P**, 4-(3,5-Difluorobenzyl)-3-isopropyl-5-methyl-1H-pyrazole **390355-20-1P**, 2-[4-[(3,5-Dichlorophenyl)sulfanyl]-3,5-dimethyl-1H-pyrazol-1-yl]ethanol **390355-22-3P**, 4-(3,5-Dichlorobenzyl)-3,5-dimethyl-1H-pyrazole **390355-37-0P**, Ethyl 3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]propanoate **390355-40-5P**, [4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]methanol **390355-42-7P**, 2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanamine **390355-45-0P**, Ethyl 4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazole-3-carboxylate **390355-46-1P**, Ethyl 4-[(3,5-dichlorophenyl)sulfanyl]-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazole-5-carboxylate **390355-83-6P**, Ethyl 4-(3,5-dichlorobenzyl)-1-(2-hydroxyethyl)-5-methyl-1H-pyrazole-3-carboxylate **390355-85-8P**, tert-Butyl [4-(3,5-dichlorobenzyl)-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-3-yl]carbamate **390355-86-9P**, 2-[3-Amino-4-(3,5-dichlorobenzyl)-5-methyl-1H-pyrazol-1-yl]ethanol **390355-87-0P**, Ethyl [4-(3,5-dichlorobenzyl)-5-methoxy-3-methyl-1H-pyrazol-1-yl]acetate **390355-88-1P**, 2-[5-Amino-4-(3,5-dichlorobenzyl)-3-ethyl-1H-pyrazol-1-yl]ethanol **390355-90-5P**, 5-[(3,5-Diethyl-1H-pyrazol-4-yl)methyl]isophthalonitrile **390355-92-7P**, 2-[4-[(3,5-Dibromophenyl)sulfanyl]-3,5-diethyl-1H-pyrazol-1-yl]ethanol
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of pyrazole derivs. as reverse transcriptase inhibitors for the treatment of HIV infection and AIDS)
RN 390355-01-8 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl- (9CI) (CA INDEX NAME)

Kamal Saeed

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-06-3 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,5-dichlorophenyl)methyl]-5-methyl-3-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-10-9 CAPLUS
CN 1H-Pyrazole, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)



RN 390355-22-3 CAPLUS
CN 1H-Pyrazole, 4-[(3,5-dichlorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 390355-37-0 CAPLUS
CN 1H-Pyrazole-1-propanoic acid, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-, ethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-16-5 CAPLUS
CN 1H-Pyrazole, 4-[(3,5-dichlorophenyl)methyl]-3-methyl-5-(1-methylethyl)-(9CI) (CA INDEX NAME)



RN 390355-17-6 CAPLUS
CN 1H-Pyrazole, 4-[(3,5-difluorophenyl)methyl]-3-methyl-5-(1-methylethyl)-(9CI) (CA INDEX NAME)



RN 390355-20-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)thio]-3,5-dimethyl- (9CI)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-40-5 CAPLUS
CN 1H-Pyrazole-1-methanol, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 390355-42-7 CAPLUS
CN 1H-Pyrazole-1-ethanamine, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-(9CI) (CA INDEX NAME)



RN 390355-45-0 CAPLUS

Kamal Saeed

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Pyrazole-3-carboxylic acid, 4-[(3,5-dichlorophenyl)thio]-5-ethyl-1-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-46-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 4-[(3,5-dichlorophenyl)thio]-3-ethyl-1-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-83-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-[(3,5-dichlorophenyl)methyl]-1-(2-hydroxyethyl)-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-87-0 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,5-dichlorophenyl)methyl]-5-methoxy-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-88-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-amino-4-[(3,5-dichlorophenyl)methyl]-3-ethyl-(9CI) (CA INDEX NAME)



RN 390355-90-5 CAPLUS

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-85-8 CAPLUS
CN Carbamic acid, [4-[(3,5-dichlorophenyl)methyl]-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 390355-86-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3-amino-4-[(3,5-dichlorophenyl)methyl]-5-methyl-(9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1,3-Benzenedicarbonitrile, 5-[(3,5-diethyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 390355-92-7 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dibromophenyl)thio]-3,5-diethyl- (9CI) (CA INDEX NAME)



IT **390355-00-7P**, 2-[4-(3,5-Dichlorobenzyl)-3-isopropyl-5-methyl-1H-pyrazol-1-yl]ethanol **390355-03-0P**, 2-[4-(3,5-Difluorobenzyl)-3-isopropyl-5-methyl-1H-pyrazol-1-yl]ethanol **390355-05-2P**, 2-[4-(3,5-Dichlorobenzyl)-5-isopropyl-3-methyl-1H-pyrazol-1-yl]ethanol **390355-07-4P**, Ethyl [4-(3,5-dichlorobenzyl)-5-isopropyl-3-methyl-1H-pyrazol-1-yl]acetate **390355-08-5P**, Ethyl [4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]acetate **390355-11-0P**, 2-[4-(3,5-Dichlorobenzyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethanol **390355-12-1P**, 2-[4-(3,5-Dichlorobenzyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanol **390355-15-4P**, Ethyl [4-(3,5-difluorobenzyl)-3-isopropyl-5-methyl-1H-pyrazol-1-yl]acetate **390355-21-2P**, 2-[4-[(3,5-Dichlorophenyl)sulfonyl]-3,5-dimethyl-1H-pyrazol-1-yl]ethanol **390355-23-4P**, 2-[4-(3,5-Dichlorobenzyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethanamine **390355-24-5P**, 2-[4-(3,5-Dichlorobenzyl)-5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanol **390355-25-6P**, 2-[4-(3,5-Dichlorobenzyl)-3-ethyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethanol **390355-26-7P**, 2-[4-(3,5-Dichlorobenzyl)-5-ethyl-3-methyl-1H-pyrazol-1-yl]ethanol **390355-27-8P**, 2-[4-(3,5-Dichlorobenzyl)-3-ethyl-5-methyl-1H-pyrazol-1-yl]ethanol **390355-28-9P**, 2-[4-(3,5-Dichlorobenzyl)-3-

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)

(dimethylamino)-5-methyl-1H-pyrazol-1-yl]ethanol **390355-30-3P**, 2-[4-(3,5-Dichlorobenzyl)-5-methoxy-3-methyl-1H-pyrazol-1-yl]ethanol **390355-31-4P**, 2-[4-(3,5-Dichlorobenzyl)-5-(2-furyl)-3-methyl-1H-pyrazol-1-yl]ethanol **390355-32-5P**, (3,5-Dichlorophenyl)[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]methanone **390355-33-6P**,

(.+-.)-2-[4-[(3,5-Dichlorophenyl)(methoxy)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethanol **390355-34-7P**, 2-[4-(2,6-Difluorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **390355-35-8P**, 2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl carbamate **390355-36-9P**, Methyl 3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]propanoate **390355-38-1P**, 3-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]propanamide **390355-39-2P**, 3-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]-1-propanol **390355-41-6P**, [4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]methyl carbamate **390355-43-8P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]benzamide **390355-44-9P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1-methyl-1H-imidazole-4-sulfonamide **390355-47-2P**, 4-[(3,5-Dichlorophenyl)sulfanyl]-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazole-3-carboxamide **390355-48-3P**,

2-[4-[(3,5-Dichlorophenyl)sulfanyl]-5-ethyl-3-(hydroxymethyl)-1H-pyrazol-1-yl]ethanol **390355-49-4P**, 3-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]-1-propanamine **390355-50-7P**,

2-[4-[(3,5-Dichlorophenyl)sulfanyl]-3-ethyl-5-(hydroxymethyl)-1H-pyrazol-1-yl]ethanol **390355-51-8P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2,2-difluoroacetamide **390355-52-9P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]ethanediamide **390355-53-0P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-6-oxo-1,6-dihydro-3-pyridazinecarboxamide **390355-54-1P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1,5-dimethyl-1H-pyrazole-3-carboxamide **390355-55-2P**, 2-[(Aminocarbonyl)amino]-N-[2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]acetamide **390355-56-3P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-ethoxyacetamide **390355-57-4P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-pyridinecarboxamide **390355-58-5P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-methoxyacetamide **390355-59-6P**,

N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-6-oxo-1,6-dihydro-2-pyridinecarboxamide **390355-60-9P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-pyrazinecarboxamide **390355-61-0P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-oxo-2H-pyran-5-carboxamide **390355-62-1P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-(1H-tetrazol-1-yl)acetamide **390355-63-2P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]tetrahydro-2-furancarboxamide **390355-64-3P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-3-hydroxybenzamide **390355-65-4P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-hydroxyacetamide **390355-66-5P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1,2,3-thiadiazole-4-carboxamide **390355-67-6P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-(dimethylamino)acetamide **390355-68-7P**, 2-Cyano-N-[2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]acetamide **390355-69-8P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-fluorobenzamide **390355-70-1P**, [4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]methyl phenyl imidodicarbonate **390355-71-2P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-N'-(2,6-difluorobenzoyl)urea **390355-72-3P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-N'-propylurea **390355-73-4P**, N-Benzoyl-N'-[2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]urea **390355-74-5P**, N-[2-[4-(3,5-Dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfonamide **390355-75-6P**, Ethyl 4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-1H-pyrazole-3-carboxylate **390355-76-7P**, [4-[(3,5-Dichlorophenyl)sulfanyl]-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-3-yl]acetonitrile **390355-77-8P**, [4-[(3,5-Dichlorophenyl)sulfonyl]-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-3-yl]acetonitrile **390355-78-9P**, 2-[4-[(3,5-Dichlorophenyl)sulfanyl]-3,5-diethyl-1H-pyrazol-1-yl]ethanol **390355-79-0P**, 4-(3,5-Dichlorobenzyl)-3-ethyl-1H-pyrazol-5-amine **390355-80-3P**, Ethyl [4-(3,5-dichlorobenzyl)-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]carbamate **390355-81-4P**, N-[4-(3,5-Dichlorobenzyl)-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]-2-methoxyacetamide **390355-82-5P**, 2-[4-(3,5-Dichlorobenzyl)-5-(dimethylamino)-3-ethyl-1H-pyrazol-1-yl]ethanol **390355-84-7P**, Ethyl 4-(3,5-dichlorobenzyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazole-5-carboxylate **390355-89-2P**, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]methyl]isophthalonitrile **390355-91-6P**, 5-[[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]methyl]isophthalonitrile **390355-93-8P**, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]sulfanyl]isophthalonitrile **390356-47-5P**, 2-[3-Amino-4-(3,5-dichlorobenzyl)-5-methyl-1H-pyrazol-1-yl]ethanol hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of pyrazole derivs. as reverse transcriptase inhibitors for the treatment of HIV infection and AIDS)

RN 390355-00-7 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-5-methyl-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 390355-03-0 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-difluorophenyl)methyl]-5-methyl-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 390355-05-2 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-3-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 390355-07-4 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,5-dichlorophenyl)methyl]-3-methyl-5-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-08-5 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-11-0 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-12-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-5-methyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 390355-15-4 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,5-difluorophenyl)methyl]-5-methyl-3-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-24-5 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-5-ethyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

RN 390355-25-6 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-3-ethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 390355-26-7 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-5-ethyl-3-methyl-(9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-21-2 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)sulfonyl]-3,5-dimethyl-(9CI) (CA INDEX NAME)



RN 390355-23-4 CAPLUS
CN 1H-Pyrazole-1-ethanamine, 4-[(3,5-dichlorophenyl)methyl]-3,5-dimethyl-(9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-27-8 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-3-ethyl-5-methyl-(9CI) (CA INDEX NAME)



RN 390355-28-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-3-(dimethylamino)-5-methyl- (9CI) (CA INDEX NAME)



RN 390355-30-3 CAPLUS

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-5-methoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 390355-31-4 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-5-(2-furanyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 390355-32-5 CAPLUS
CN Methanone, (3,5-dichlorophenyl)[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-33-6 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methoxymethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 390355-34-7 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(2,6-difluorophenyl)methyl]-3,5-diethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 390355-35-8 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-, carbamate (ester) (9CI) (CA INDEX NAME)



RN 390355-36-9 CAPLUS
CN 1H-Pyrazole-1-propanoic acid, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 390355-38-1 CAPLUS
CN 1H-Pyrazole-1-propanamide, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-39-2 CAPLUS
CN 1H-Pyrazole-1-propanol, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 390355-41-6 CAPLUS
CN 1H-Pyrazole-1-methanol, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-, carbamate (ester) (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 390355-43-8 CAPLUS
CN Benzamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 390355-44-9 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 390355-47-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(3,5-dichlorophenyl)thio]-5-ethyl-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 390355-50-7 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)thio]-3-ethyl-5-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 390355-51-8 CAPLUS
CN Acetamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2,2-difluoro- (9CI) (CA INDEX NAME)



RN 390355-52-9 CAPLUS
CN Ethanediamide, [2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-48-3 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)thio]-5-ethyl-3-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 390355-49-4 CAPLUS
CN 1H-Pyrazole-1-propanamine, 4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-53-0 CAPLUS
CN 3-Pyridazinecarboxamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 390355-54-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 390355-55-2 CAPLUS
CN Acetamide, 2-[(aminocarbonyl)amino]-N-[2-[4-[(3,5-dichlorophenyl)methyl]-

Kamal Saeed

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 390355-56-3 CAPLUS
CN Acetamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-ethoxy- (9CI) (CA INDEX NAME)



RN 390355-57-4 CAPLUS
CN 2-Pyridinecarboxamide,
N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-60-9 CAPLUS
CN Pyrazinecarboxamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 390355-61-0 CAPLUS
CN 2H-Pyran-5-carboxamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 390355-62-1 CAPLUS
CN 1H-Tetrazole-1-acetamide,
N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-58-5 CAPLUS
CN Acetamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 390355-59-6 CAPLUS
CN 2-Pyridinecarboxamide,
N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-63-2 CAPLUS
CN 2-Furancarboxamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 390355-64-3 CAPLUS
CN Benzamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 390355-65-4 CAPLUS
CN Acetamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-hydroxy- (9CI) (CA INDEX NAME)

09899322

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-66-5 CAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 390355-67-6 CAPLUS
CN Acetamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-70-1 CAPLUS
CN Imidodicarbonic acid, [4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]methyl phenyl ester (9CI) (CA INDEX NAME)



RN 390355-71-2 CAPLUS
CN Benzamide, N-[[[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 390355-72-3 CAPLUS

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-68-7 CAPLUS
CN Acetamide, 2-cyano-N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 390355-69-8 CAPLUS
CN Benzamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-2-fluoro- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Urea, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-N'-propyl- (9CI) (CA INDEX NAME)



RN 390355-73-4 CAPLUS
CN Benzamide, N-[[[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 390355-74-5 CAPLUS
CN 5-Pyrimidinesulfonamide, N-[2-[4-[(3,5-dichlorophenyl)methyl]-3,5-diethyl-1H-pyrazol-1-yl]ethyl]-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)

Kamal Saeed

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-75-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-[(3,5-dichlorophenyl)thio]-5-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-76-7 CAPLUS
CN 1H-Pyrazole-3-acetonitrile, 4-[(3,5-dichlorophenyl)thio]-5-ethyl-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-80-3 CAPLUS
CN Carbamic acid, [4-[(3,5-dichlorophenyl)methyl]-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-81-4 CAPLUS
CN Acetamide, N-[4-[(3,5-dichlorophenyl)methyl]-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]-2-methoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 390355-77-8 CAPLUS
CN 1H-Pyrazole-3-acetonitrile, 4-[(3,5-dichlorophenyl)sulfonyl]-5-ethyl-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 390355-78-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)thio]-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 390355-79-0 CAPLUS
CN 1H-Pyrazol-3-amine, 4-[(3,5-dichlorophenyl)methyl]-5-ethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 390355-82-5 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-[(3,5-dichlorophenyl)methyl]-5-(dimethylamino)-3-ethyl- (9CI) (CA INDEX NAME)



RN 390355-84-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 4-[(3,5-dichlorophenyl)methyl]-1-(2-hydroxyethyl)-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 390355-89-2 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390355-91-6 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 390355-93-8 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thio]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:31482 CAPLUS
DOCUMENT NUMBER: 136:79802
TITLE: Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
INVENTOR(S): Pillarisetti, Sivaram; Goldberg, Itzhak D.
PATENT ASSIGNEE(S): North Shore-Long Island Jewish Health System, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002593	A2	20020110	WO 2001-US20849	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001077854	A5	20020114	AU 2001-77854	20010629
PRIORITY APPLN. INFO.:			US 2000-606628	A2 20000629
			WO 2001-US20849	W 20010629

OTHER SOURCE(S): MARPAT 136:79802

AB The invention is directed to small org. mols. and peptides having the ability to mimic or agonize hepatocyte growth factor/ scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.

IT **261349-35-3 387352-92-3 387352-93-4 387352-94-5 387352-95-6 387352-96-7 387352-97-8 387352-98-9 387352-99-0 387353-00-6 387353-01-7**
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptide and small-mol. modulators of cellular proliferation and angiogenesis)

RN 261349-35-3 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-3,5-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 390356-47-5 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3-amino-4-[(3,5-dichlorophenyl)methyl]-5-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 387352-92-3 CAPLUS
CN 1H-Pyrazole, 4-[(2,6-dichlorophenyl)methyl]-1-[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 387352-93-4 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-1-[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 387352-94-5 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-1-[(3,4-dichlorophenyl)sulfonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 387352-95-6 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-1,3,5-trimethyl- (9CI) (CA INDEX NAME)



RN 387352-96-7 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 387352-97-8 CAPLUS

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 387353-00-6 CAPLUS
CN 1H-Pyrazole, 1-(4-chlorobenzoyl)-4-[(2-chloro-6-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 387353-01-7 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-3,5-dimethyl-1-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Pyrazole-1-propanenitrile, 4-[(2,6-dichlorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 387352-98-9 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-1-(2,6-dichlorobenzoyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 387352-99-0 CAPLUS
CN 1H-Pyrazole, 4-[(2-chloro-6-fluorophenyl)methyl]-1-(2,2-dimethyl-1-oxopropyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:851126 CAPLUS
DOCUMENT NUMBER: 135:371760
TITLE: Preparation of pyrazolylpyrimidines and analogs as TNF-.alpha. signaling modulators
INVENTOR(S): Sneddon, Scott F.; Kane, John L.; Hirth, Bradford H.; Vinick, Fred; Qiao, Shuang; Nahill, Sharon R.
PATENT ASSIGNEE(S): Genzyme Corporation, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087849	A2	20011122	WO 2001-US15027	20010510
WO 2001087849	A3	20020606		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002119988	A1	20020829	US 2001-852965	20010510
PRIORITY APPLN. INFO.:			US 2000-203784P	P 20000512
			US 2000-205213P	P 20000518

OTHER SOURCE(S): MARPAT 135:371760
GI



AB Title compds. [I; R1 = H or NH2; R2 = ZZ3(CH2)nR; R = (un)substituted Ph or -heterocyclyl; R4 = (alkyl-substituted) 2-pyridinyl or -pyrazinyl; Z = (un)substituted pyrazole-1,4-diyl; Z1,Z2 = N or CH; Z3 = O, CH2, S, SO2; n = 0-2] were prepd. Thus, 4-(Me2HC)C6H4OH was condensed with (MeCO)2CHN2 and the product cyclocondensed with 4-(2-pyridinyl)-2-pyrimidinylhydrazine to give title compd. II. Data for biol. activity of I were given.
IT 374080-91-8P
RL: BAC (Biological activity or effector, except adverse); BSU
...logical

09899322

L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazolylpyrimidines and analogs as TNF-.alpha. signaling modulators)
RN 374080-91-8 CAPLUS
CN Pyrimidine,
2-[4-[(3,4-dichlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
activity)
RN 157433-74-4 CAPLUS
CN Methanone,
[5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



Cl

RN 157434-46-3 CAPLUS
CN Methanone, [5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(methylthio)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 157434-48-5 CAPLUS
CN Methanone,
[5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:568540 CAPLUS
DOCUMENT NUMBER: 133:164062
TITLE: Preparation of pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
INVENTOR(S): Faraci, William Stephen; Welch, Willard Mckowan, Jr.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S., 22 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6103900	A	20000815	US 1997-961413	19971030
US 2002049227	A1	20020425	US 1999-377569	19990819
US 6448265	B2	20020910		

PRIORITY APPLN. INFO.: US 1992-992225 B3 19921217
WO 1993-US10359 W 19931103
US 1995-448529 A3 19950614
US 1997-961413 A3 19971030
OTHER SOURCE(S): MARPAT 133:164062
GI



I

AB The title compds. [I; A and R1 together with the carbons to which they are
attached form (un)substituted pyrimidinyl; A = CO; R1 = NH2; R2 = H, alkyl, OH, etc.; R3 = (un)substituted Ph, naphthyl, 3-8 membered cycloalkyl, etc.; R4 = 2,4,6-Cl3C6H2; 2,4,6-Me3C6H2, 2,6-Cl2-4-F3CC6H2, 4-Br-2,6-Me2C6H2] which have corticotropin releasing factor (CRF) antagonist activity, and therefore are effective in the treatment of a wide range of diseases including stress-related illnesses, were prepd. E.g., a multi-step synthesis of I [A = CO; R1 = NH2; R2 = SMe; R3 = 2,5-Me2C6H3; R4 = 2,6-Cl2-4-F3CC6H2] was given. The binding activity of compds. I to a CRF receptor generally ranges from 0.2 nM - 10 .mu.M.
IT **157433-74-4P 157434-46-3P 157434-48-5P**
157434-53-2P 157434-54-3P 157434-55-4P
157434-56-5P 252555-18-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazoles and pyrazolopyrimidines having CRF antagonistic

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-53-2 CAPLUS
CN Methanone,
[5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)



RN 157434-54-3 CAPLUS
CN Methanone, [5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(methylthio)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)

Kamal Saeed

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-55-4 CAPLUS
CN Methanone, [5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-(methylthio)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)



RN 157434-56-5 CAPLUS
CN Methanone,
[5-amino-3-(methylthio)-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 252555-18-3 CAPLUS
CN Methanone, [5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-(methylthio)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:808685 CAPLUS
DOCUMENT NUMBER: 132:35715
TITLE: Preparation of pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
INVENTOR(S): Faraci, William Stephen; Welch, Willard McKowan, Jr.
PATENT ASSIGNEE(S): Pfeizer Inc., USA
SOURCE: U.S., 19 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6005109	A	19991221	US 1997-961414	19971030
US 2002016333	A1	20020207	US 1999-377350	19990819
US 6441018	B2	20020827		

PRIORITY APPLN. INFO.: US 1992-992225 B2 19921217
WO 1993-US10359 W 19931103
US 1995-448529 A3 19950614
US 1997-961414 A3 19971030

OTHER SOURCE(S): MARPAT 132:35715
GI



I

AB The title compds. [I; A = CO; A together with the carbons to which they are attached forms (un)substituted 5-pyridyl; R2 = H, alkyl, OH, etc.; R3 = (un)substituted Ph, naphthyl, 3-8 membered cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, 9-12 membered bicycloalkyl] which have corticotropin releasing factor (CRF) antagonist activity and therefore are useful in the treatment of a wide range of diseases including stress-related illnesses, were prepd. E.g., a 4-step detailed synthesis of I [A = CO; R1 = NH2; R2 = SMe; R3 = 2,5-Me2C6H3; R4 = 2,6-Cl2-4-F3CC6H2], starting with p-xylene and .alpha.-bromoacetyl chloride, was given. The binding activity for compds. I generally ranges from about 0.2 nM - 10 .mu.M.

IT **157433-74-4P 157434-46-3P 157434-48-5P 157434-53-2P 157434-54-3P 157434-55-4P 157434-56-5P 252555-18-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazoles and pyrazolopyrimidines having CRF antagonistic activity)

RN 157433-74-4 CAPLUS

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Methanone,
[5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 157434-46-3 CAPLUS
CN Methanone, [5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(methylthio)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 157434-48-5 CAPLUS
CN Methanone,
[5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-53-2 CAPLUS
CN Methanone, [5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)



RN 157434-54-3 CAPLUS
CN Methanone, [5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(methylthio)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 252555-18-3 CAPLUS
CN Methanone, [5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-(methylthio)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-55-4 CAPLUS
CN Methanone, [5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-(methylthio)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)



RN 157434-56-5 CAPLUS
CN Methanone, [5-amino-3-(methylthio)-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:485043 CAPLUS
DOCUMENT NUMBER: 129:95490
TITLE: Preparation of substituted 4-benzoylpyrazoles as herbicides.
INVENTOR(S): Hill, Regina Luise; Kardorff, Uwe; Rack, Michael; Gotz, Norbert; Baumann, Ernst; Von Deyn, Wolfgang; Engel, Stefan; Mayer, Guido; Otten, Martina; Reinheimer, Joachim; Witschel, Matthias; Misslitz, Ulf; Walter, Helmut; Westphalen, Karl-otto
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: PCT Int. Appl., 296 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9829392	A1	19980709	WO 1997-EP7210	19971219
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19700096	A1	19980709	DE 1997-19700096	19970103
AU 9860908	A1	19980731	AU 1998-60908	19971219
AU 744201	B2	20020221		
EP 960100	A1	19991201	EP 1997-954936	19971219
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT				
CN 1247532	A	20000315	CN 1997-181884	19971219
BR 9714257	A	20000418	BR 1997-14257	19971219
JP 2001508421	T2	20010626	JP 1998-529588	19971219
ZA 9800007	A	19990702	ZA 1998-7	19980102
US 6028035	A	20000222	US 1999-331671	19990623
PRIORITY APPLN. INFO.:			DE 1997-19700096 A	19970103
			WO 1997-EP7210 W	19971219

OTHER SOURCE(S): MARPAT 129:95490
GI



I

AB Title compds. [I; R1, R2 = H, NO2, halo, cyano, rhodano, alkyl, haloalkyl, alkoxyalkyl, alkenyl, alkynyl, OR5, OCOR6, OSO2R6, SH, SOnR7, SO2OR5, SO2NR5R8, NR8SO2R6, NR8COR6; R3 = H, cyano, alkyl, haloalkyl, OR7, SR7, NR7R10; R4 = H, (substituted) alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, COR9, CO2R9, COSR9 CONR8R9; X = O, NR8; n = 0, 1, 2; R5 = H, alkyl, haloalkyl, alkoxyalkyl, alkenyl, alkynyl; R6 = alkyl, haloalkyl; R7

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)

= alkyl, haloalkyl, alkoxyalkyl, alkenyl, alkynyl; R8 = H, alkyl; R9 = alkyl, alkenyl, alkynyl, Ph, PhCH2; R10 = alkyl, haloalkyl, alkenyl, alkynyl; Q = substituted pyrazol-4-yl], were prepd. as herbicides (no data). Thus, 2,4-dichloro-3-ethoxyiminomethylbenzoic acid, 2-ethyl-3-hydroxypyrazole, and DCC were stirred 12 h in MeCN at room temp.

to give 4-(2,4-dichloro-3-ethoxyiminomethylbenzoyl)-2-ethyl-3-hydroxypyrazole.

IT **209795-47-1P 209795-48-2P 209795-49-3P 209795-50-6P 209795-51-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted 4-benzoylpyrazoles as herbicides)

RN 209795-47-1 CAPLUS

CN Benzaldehyde, 2,6-dichloro-3-[(1-ethyl-5-hydroxy-1H-pyrazol-4-yl)carbonyl]-, 1-(O-2-propynyloxime) (9CI) (CA INDEX NAME)



RN 209795-48-2 CAPLUS

CN Benzaldehyde, 2,6-dichloro-3-[(1-ethyl-5-hydroxy-1H-pyrazol-4-yl)carbonyl]-, 1-(O-ethyloxime) (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209795-51-7 CAPLUS

CN Benzaldehyde, 3-[(1-butyl-5-hydroxy-1H-pyrazol-4-yl)carbonyl]-2,6-dichloro-, 1-(O-methyloxime) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209795-49-3 CAPLUS

CN Benzaldehyde, 2,6-dichloro-3-[(1-ethyl-5-hydroxy-1H-pyrazol-4-yl)carbonyl]-, 1-(O-methyloxime) (9CI) (CA INDEX NAME)



RN 209795-50-6 CAPLUS

CN Benzaldehyde, 2,6-dichloro-3-[(5-hydroxy-1-propyl-1H-pyrazol-4-yl)carbonyl]-, 1-(O-methyloxime) (9CI) (CA INDEX NAME)

L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:640250 CAPLUS

DOCUMENT NUMBER: 127:331482

TITLE: Preparation of 1-thiocarbamoyl-5-hydroxypyrazoles as agrochemical and medical microbicides

INVENTOR(S): Wachtler, Peter; Heuer, Lutz; Kugler, Martin; Schrage, Heinrich

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: U.S., 28 pp., Cont.-in-part of U.S. 5,510,365. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5672617	A	19970930	US 1996-598878	19960209
DE 4411243	A1	19951005	DE 1994-4411243	19940331
DE 4414792	A1	19950216	DE 1994-4414792	19940428
US 5510365	A	19960423	US 1994-286080	19940804
DE 19510058	A1	19960926	DE 1995-19510058	19950320

PRIORITY APPLN. INFO.: DE 1993-4326904 A 19930811
DE 1994-4411243 A 19940331
DE 1994-4414792 A 19940428
US 1994-286080 A2 19940804
DE 1995-19510058 A 19950320

OTHER SOURCE(S): MARPAT 127:331482

GI



I

AB Title compds. I [R1,R2 = H, (ar)alkyl, aryl, etc.; R1 = H and R2 = NH2; R3,R4 = H, (ar)alkyl, alkoxy, (hetero)aryl, etc.; R3R4 = atoms to form a ring] were prepd. Thus, BuCH(CHO)CO2Et was cyclocondensed with H2NNHCSNH2 to give I (R1-R3 = H, R4 = Bu). Data for biol. activity of I were given.

IT **146120-29-8P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 1-thiocarbamoyl-5-hydroxypyrazoles as agrochem. and medical microbicides)

RN 146120-29-8 CAPLUS

CN 1H-Pyrazole-1-carbothioamide, 4-[(2,4-dichlorophenyl)methyl]-5-hydroxy- (9CI) (CA INDEX NAME)

09899322

L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186195-90-4 CAPLUS
CN 1H-Pyrazol-3-amine, 4-[(2,6-difluorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 186195-92-6 CAPLUS
CN 1H-Pyrazol-3-amine, 4-[(2-chloro-6-fluorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:113350 CAPLUS
DOCUMENT NUMBER: 126:117969
TITLE: Preparation of 3-amino-4-aryl(methyl)pyrazoles as antiepileptics.
INVENTOR(S): Menzer, Manfred; Lankau, Hans-Joachim; Unverferth, Klaus
PATENT ASSIGNEE(S): Arzneimittelwerk Dresden Gmbh, Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19521822	A1	19961219	DE 1995-19521822	19950616

PRIORITY APPLN. INFO.: DE 1995-19521822 19950616
OTHER SOURCE(S): MARPAT 126:117969
GI



AB Title compds. (I; n = 0, 1; R = H, Me; X = Me, CF3, F, Cl; Y = H, F, Cl), were prepd. Thus, I (n = 0; X, Y = Cl; R = H) (prepn. outlined) at 30 mg/kg orally in mice gave 100% inhibition of electroshock-induced convulsion.

IT **186195-88-0P 186195-90-4P 186195-92-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-amino-4-aryl(methyl)pyrazoles as antiepileptics)
RN 186195-88-0 CAPLUS
CN 1H-Pyrazol-3-amine, 4-[(2,6-dichlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:623122 CAPLUS
DOCUMENT NUMBER: 125:247809
TITLE: Preparation of pyrazole derivatives as herbicides
INVENTOR(S): Morimoto, Katsushi; Ogura, Tomoyuki; Nagaoka, Takeshi; Furusawa, Hiroyuki; Nishio, Koichi; Ishii, Shigeru; Nawamaki, Tsutomu; Nakahira, Kunimitsu; Ishikawa, Kimihiro
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9624589	A1	19960815	WO 1996-JP260	19960207
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
AU 9646326	A1	19960827	AU 1996-46326	19960207
EP 822187	A1	19980204	EP 1996-901955	19960207
R: DE, FR, GB				
US 5939559	A	19990817	US 1997-875499	19971027
US 6030926	A	20000229	US 1998-210890	19981216

PRIORITY APPLN. INFO.: JP 1995-18981 19950207
JP 1996-4631 19960116
WO 1996-JP260 19960207
OTHER SOURCE(S): MARPAT 125:247809
GI



I



II

AB The title compds., e. g. I [R1 represents hydrogen or a protecting group ;
R2 and R3 represent each Ph, 1-naphthyl, 2-naphthyl, a 5- or 6-membered heterocycle, etc.; and R4 represents hydrogen, halogeno, alkyl, alkoxy or alkylthio], are prepd. The title compd. II (prepn. given) (at 5 Kg/ha) gave complete control of Abutilon avicennae and Amaranthus retroflexus.

IT **182141-12-4P 182141-82-8P 182141-84-0P**
182142-38-7P 182142-56-9P

Kamal Saeed

L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazole derivs. as herbicides)
RN 182141-12-4 CAPLUS
CN Methanone, (3,4-dichlorophenyl)[3-(2-thienyl)-1H-pyrazol-4-yl]- (9CI) (CA
INDEX NAME)



RN 182141-82-8 CAPLUS
CN Methanone, (2,5-dichlorophenyl)(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA
INDEX NAME)



RN 182141-84-0 CAPLUS
CN Methanone, (2,4-dichlorophenyl)(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA
INDEX NAME)

L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 182142-38-7 CAPLUS
CN Methanone, (3,5-difluorophenyl)(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA
INDEX NAME)



RN 182142-56-9 CAPLUS
CN Methanone, (3,4-difluorophenyl)(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA
INDEX NAME)



L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:171879 CAPLUS
DOCUMENT NUMBER: 124:220541
TITLE: Corticotropin-releasing factor antagonists for treatment of stress-related disorders
INVENTOR(S): Bright, Gene M.; Chen, Yuhpyng L.; Welch, Willard M., Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 691128	A1	19960110	EP 1995-201475	19950606
EP 691128	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5646152	A	19970708	US 1994-259835	19940615
AT 229334	E	20021215	AT 1995-201475	19950606
CA 2151674	AA	19951216	CA 1995-2151674	19950613
AU 9521691	A1	19951221	AU 1995-21691	19950614
AU 701963	B2	19990211		
JP 08003041	A2	19960109	JP 1995-170453	19950614
HU 71602	A2	19960129	HU 1995-1738	19950614
ZA 9504921	A	19961217	ZA 1995-4921	19950614
US 6200979	B1	20010313	US 1997-796096	19970205

PRIORITY APPLN. INFO.: US 1994-259835 A 19940615
AB Substituted pyrazoles and pyrazolopyrimidines (Markush structures is given) have ACTH-releasing factor antagonist activity and are useful in the treatment of a variety of stress-related disorders (no data).
IT **157434-55-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(ACTH-releasing factor antagonists for treatment of stress-related disorders)
RN 157434-55-4 CAPLUS
CN Methanone, [5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-(methylthio)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)

09899322

L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:452224 CAPLUS
DOCUMENT NUMBER: 122:214074
TITLE: Preparation of 1-thiocarbamoyl-5-hydroxypyrazoles for treatment of septic shock
INVENTOR(S): Wachtler, Peter; Heuer, Lutz; Sperzel, Michael; Stuenkel, Klaus Georg
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 49 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 638556	A1	19950215	EP 1994-111858	19940729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4414792	A1	19950216	DE 1994-4414792	19940428
JP 07076575	A2	19950320	JP 1994-202936	19940805
CA 2129701	AA	19950212	CA 1994-2129701	19940808

PRIORITY APPLN. INFO.: DE 1993-4326904 A 19930811
DE 1994-4414792 A 19940428
OTHER SOURCE(S): MARPAT 122:214074
GI



I

AB Title compds. [I; R1,R2 = H, (cyclo)alkyl, alkenyl, aryl, etc.; R1 = H and R2 = NH2; R3,R4 = H, (cyclo)alk(en)yl, alkoxy, (hetero)aryl(oxy), etc.; R3R4 = atoms to complete a ring] were prepd. Thus, PrCOCH2CO2Et was cyclocondensed with H2NCSNHNH2 to give I (R1 = R2 = R4 = H)(II; R3 = Pr). II (R3 = CH2CH2CHMe3) protected mice from LPS-induced septic shock at .ltoreq.10mg/kg i.v.

IT **146120-29-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-thiocarbamoyl-5-hydroxypyrazoles for treatment of septic shock)

RN 146120-29-8 CAPLUS
CN 1H-Pyrazole-1-carbothioamide, 4-[(2,4-dichlorophenyl)methyl]-5-hydroxy- (9CI) (CA INDEX NAME)

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:557639 CAPLUS
DOCUMENT NUMBER: 121:157639
TITLE: Pyrazoles and pyrazolopyrimidines having corticotropin-releasing factor antagonist activity
INVENTOR(S): Faraci, William Stephen; Welch, Willard McKowan, Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9413643	A1	19940623	WO 1993-US10359	19931103
W: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2150483	AA	19940623	CA 1993-2150483	19931103
AU 9454548	A1	19940704	AU 1994-54548	19931103
AU 690527	B2	19980430		
EP 674624	A1	19951004	EP 1993-925103	19931103
EP 674624	B1	19990120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07509725	T2	19951026	JP 1993-514147	19931103
JP 2862374	B2	19990303		
CZ 284157	B6	19980812	CZ 1995-1585	19931103
AT 175961	E	19990215	AT 1993-925103	19931103
PL 175831	B1	19990226	PL 1993-309356	19931103
ES 2126661	T3	19990401	ES 1993-925103	19931103
BR 9307659	A	19990629	BR 1993-7659	19931103
RU 2142946	C1	19991220	RU 1995-113969	19931103
IL 107946	A1	19980924	IL 1993-107946	19931209
HU 67457	A2	19950428	HU 1993-3591	19931215
ZA 9309404	A	19950615	ZA 1993-9404	19931215
FI 9305674	A	19940618	FI 1993-5674	19931216
CN 1092768	A	19940928	CN 1993-120120	19931216
CN 1060768	B	20010117		
US 5712303	A	19980127	US 1995-448529	19950614
NO 9502395	A	19950816	NO 1995-2395	19950616
AU 9878431	A1	19981001	AU 1998-78431	19980727
AU 713804	B2	19991209		
NO 9805494	A	19950816	NO 1998-5494	19981125
US 2002016333	A1	20020207	US 1999-377350	19990819
US 6441018	B2	20020827		
US 2002049227	A1	20020425	US 1999-377569	19990819
US 6448265	B2	20020910		

PRIORITY APPLN. INFO.: US 1992-992225 A 19921217
WO 1993-US10359 W 19931103
US 1995-448529 A3 19950614
US 1997-961413 A3 19971030
US 1997-961414 A3 19971030
OTHER SOURCE(S): MARPAT 121:157639
GI

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



I



II



III

AB Pyrazoles and pyrazolopyrimidines I (R1H, alkyl, amino, etc.; R2 = H, alkyl, alkoxy, etc.; R3, R4 = Ph, naphthyl, thenyl, etc.; A = CO, SO2; AR1 = pyrimidinyl or pyridinyl group) were disclosed. I have ACTH releasing factor antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses, such as depression, headaches, inflammatory disorders, fertility disorders, etc. Prepd. example compds. are 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(2,5-dimethylbenzoyl)-3-(methylthio)pyrazole (II) and 4-(2-chlorophenyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(methylthio)pyrazolo[3,4]pyrimidine (III).

IT **157433-74-4P 157434-46-3P 157434-47-4P 157434-48-5P 157434-53-2P 157434-54-3P 157434-55-4P 157434-56-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as ACTH-releasing factor antagonist)

RN 157433-74-4 CAPLUS
CN Methanone, [5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-46-3 CAPLUS
CN Methanone, [5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(methylthio)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 157434-47-4 CAPLUS
CN Methanone, [5-amino-1-(4-bromo-2,6-dichlorophenyl)-3-(methylthio)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-48-5 CAPLUS
CN Methanone, [5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 157434-53-2 CAPLUS
CN Methanone, [5-amino-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-54-3 CAPLUS
CN Methanone, [5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(methylthio)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)



RN 157434-55-4 CAPLUS
CN Methanone, [5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-(methylthio)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)

Kamal Saeed

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 157434-56-5 CAPLUS
CN Methanone, [5-amino-3-(methylthio)-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-yl](2,5-dibromophenyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 130689-98-4 CAPLUS
CN Methanone, (3,4-dichlorophenyl)(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:177 CAPLUS
DOCUMENT NUMBER: 114:177
TITLE: Antiviral activity of certain acylpyrazolones
AUTHOR(S): Galabov, A.; Terebenina, A.; Dimitrova, K.; Todorova, O.; Karparov, A.; Borisov, G.
CORPORATE SOURCE: Inst. Microbiol., Sofia, Bulg.
SOURCE: Doklady Bolgarskoi Akademii Nauk (1990), 43(5), 61-4
CODEN: DBANAD; ISSN: 0366-8681
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB This study examd. the antiviral activity of some derivs. of 3-methyl-1-phenyl-pyrazolone-5 (MPP-5, I) as well as their complexes with copper, zinc, iron and manganese. The results show that almost always active are the 4-substituted acyclic derivs., giving chelated complexes with a lot of metals. This allows the assumption that the biol. activity is related to transfer of metals.

IT **74451-93-7 130689-98-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antiviral activity of, structure in relation to)

RN 74451-93-7 CAPLUS
CN Methanone, (2,4-dichlorophenyl)(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



09899322

=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	67.31	369.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.11	-9.11

STN INTERNATIONAL LOGOFF AT 13:17:38 ON 16 JAN 2003

Kamal Saeed